Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit

Rhea-AI Summary

Solid Biosciences Inc. (Nasdaq: SLDB) announced its participation in the Jefferies Gene Therapy/Editing Summit on October 28, 2021, at 2:00 p.m. ET. Co-Founder and CEO Ilan Ganot, along with Chief Scientific Officer Carl Morris, will engage in a fireside chat. Investors can access a live webcast on the company’s investor relations website, with a replay available afterward. The company focuses on developing therapies for Duchenne muscular dystrophy, particularly through its gene therapy candidate, SGT-001.

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and Chief Executive Officer, and Carl Morris, PhD, Chief Scientific Officer, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Thursday, October 28, 2021 at 2:00 p.m. ET.

A live webcast of this fireside chat will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Caitlin Lowie
Solid Bio
607-423-3219
clowie@solidbio.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com

FAQ

When will Solid Biosciences participate in the Jefferies Gene Therapy/Editing Summit?

Solid Biosciences will participate in the Jefferies Gene Therapy/Editing Summit on October 28, 2021.

Who will represent Solid Biosciences at the Jefferies Summit?

Ilan Ganot, Co-Founder and CEO, and Carl Morris, Chief Scientific Officer, will represent Solid Biosciences.

How can I watch the Solid Biosciences fireside chat?

You can watch the live webcast of the fireside chat on Solid Biosciences' investor relations website.

What is the focus of Solid Biosciences?

Solid Biosciences focuses on advancing therapies for Duchenne muscular dystrophy.

What is SLDB's lead gene therapy candidate?

SLDB's lead gene therapy candidate is SGT-001.